JP2012522007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522007A5
JP2012522007A5 JP2012502295A JP2012502295A JP2012522007A5 JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5 JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
oxazin
oxo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522007A (ja
JP5730281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028878 external-priority patent/WO2010111626A2/en
Publication of JP2012522007A publication Critical patent/JP2012522007A/ja
Publication of JP2012522007A5 publication Critical patent/JP2012522007A5/ja
Application granted granted Critical
Publication of JP5730281B2 publication Critical patent/JP5730281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502295A 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 Active JP5730281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16413209P 2009-03-27 2009-03-27
US61/164,132 2009-03-27
PCT/US2010/028878 WO2010111626A2 (en) 2009-03-27 2010-03-26 Poly (adp-ribose) polymerase (parp) inhibitors

Publications (3)

Publication Number Publication Date
JP2012522007A JP2012522007A (ja) 2012-09-20
JP2012522007A5 true JP2012522007A5 (enExample) 2013-05-16
JP5730281B2 JP5730281B2 (ja) 2015-06-10

Family

ID=42288484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502295A Active JP5730281B2 (ja) 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤

Country Status (4)

Country Link
US (1) US8669249B2 (enExample)
EP (1) EP2415767B1 (enExample)
JP (1) JP5730281B2 (enExample)
WO (1) WO2010111626A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
EA025322B1 (ru) 2011-12-22 2016-12-30 Новартис Аг Производные дигидробензооксазина и дигидропиридооксазина
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2014184272A2 (en) * 2013-05-14 2014-11-20 Medizinische Hochschule Hannover Means and methods for treating cancer
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
SI3674302T1 (sl) 2014-04-23 2023-07-31 Incyte Holdings Corporation 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CR20190027A (es) 2016-06-20 2019-05-16 Incyte Corp Formas sólidas cristalinas de un inhibidor de bet
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
US20210052597A1 (en) 2018-01-29 2021-02-25 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
CN110526907B (zh) * 2018-05-23 2021-04-23 四川大学 苯并噁嗪酮类衍生物及其应用
US12312337B2 (en) 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
CN114144413B (zh) * 2019-07-19 2024-08-16 阿斯利康(瑞典)有限公司 Parp1抑制剂
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3213029A1 (en) * 2021-04-22 2022-10-27 Yuli Xie Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN115232154A (zh) * 2021-04-23 2022-10-25 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
US20240391937A1 (en) * 2021-09-30 2024-11-28 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
MX2024006074A (es) * 2021-11-19 2024-06-28 Kangbaida Sichuan Biotechnology Co Ltd Inhibidor de parp1 selectivo y aplicacion del mismo.
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds
CN119487027A (zh) * 2022-04-28 2025-02-18 宁波新湾科技发展有限公司 作为parp1抑制剂的化合物
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
KR20250128449A (ko) * 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0313311A3 (en) 1987-10-20 1990-03-07 Ici Australia Operations Proprietary Limited Herbicidal sulfonamides
US6191127B1 (en) 1997-05-02 2001-02-20 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
JP2002524399A (ja) 1998-09-09 2002-08-06 石原産業株式会社 除草剤として有用な縮合ベンゼン誘導体
BR9914040A (pt) * 1998-09-22 2002-01-15 Kyowa Hakko Kogyo Kk Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios
DE10056312A1 (de) * 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
US8022382B2 (en) * 2005-03-11 2011-09-20 Taiwan Semiconductor Manufacturing Company, Ltd. Phase change memory devices with reduced programming current
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
US20080221093A1 (en) * 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a heterocyclic moiety

Similar Documents

Publication Publication Date Title
JP2012522007A5 (enExample)
CA2793086C (en) Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
AU2005292152B2 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
JP5753194B2 (ja) 治療用化合物、及び関連する使用の方法
JP2013542937A5 (enExample)
JP6121658B2 (ja) 治療用化合物、及び関連する使用の方法
AU2012296411B2 (en) Amino quinazolines as kinase inhibitors
CA2729408C (en) Triazole derivative or salt thereof
EP2807157A1 (en) 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO1995018097A1 (en) Anthranilic acid derivative
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
CA2967894A1 (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
JP2017512794A5 (enExample)
JP2009531309A5 (enExample)
NZ763263A (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
ES2539290T3 (es) Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso
CA2879816C (en) Methanethione compounds having antiviral activity
EP2627652B1 (en) Pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof
JP7616609B2 (ja) Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体
KR101127725B1 (ko) 아미드 유도체
AU2023317959A1 (en) Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
RU2821520C2 (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
HK1227751A1 (en) Therapeutic compounds and related methods of use